ObsEva, a biotech company focused on women’s reproductive health has appointed Will Brown as Chief Financial Officer and member of the company’s Executive Committee, effective January 1, 2022.

Will Brown is a Certified Public Accountant with deep experience in capital markets, accounting, and finance. Mr. Brown joins ObsEva from Altimmune, Inc. (NASDAQ: ALT) where he served as Chief Financial Officer and was critical in the company’s transformation and growth through more than $300 million of new equity issuances and a strategic acquisition. Mr. Brown has been a consultant to several private and public companies in a variety of accounting and tax matters both independently and as the managing partner of Redmont CPAs. Prior to his consulting role, he was an audit manager at PricewaterhouseCoopers and a Division Controller at Rheem, a multinational manufacturing company. Mr. Brown earned both his MBA and B.S. from Auburn University at Montgomery.

“We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva’s executive team,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “This is an exciting time for ObsEva on the heels of the recent NDA acceptance from the FDA for linzagolix — which if approved, would be the first and only GnRH receptor antagonist with flexible dosing options for uterine fibroids — and the anticipated MAA recommendation from the CHMP in Q4 2021. We are confident that Will’s impressive track record will be invaluable as we continue to advance linzagolix towards commercialization and explore new indications and partnerships to maximize the value of our pipeline candidates.”

Mr. Brown added, “I am excited to join ObsEva at this critical inflection point and build on the significant business development, clinical, and regulatory achievements over the last year. I look forward to driving this momentum forward and working with the impressive ObsEva team to create long-term value for shareholders and deliver on our mission to advance the field of women’s health by offering more individualized treatment options.”

Show CommentsClose Comments

Leave a comment